Selective use of radioactive iodine in intermediate-risk papillary thyroid cancer.

OBJECTIVE To describe the outcomes with the selective use of radioactive iodine (RAI) in patients who are at intermediate risk of death from papillary thyroid cancer, focusing on 2 subgroups: patients older than 45 years with low-risk tumors and patients younger than 45 years with high-risk tumors. DESIGN Retrospective case review. SETTING Tertiary referral US cancer center. PATIENTS The study incluced 532 consecutive patients who were surgically treated between 1986 and 2005. INTERVENTIONS All patients underwent total thyroidectomy; 307 also received RAI. MAIN OUTCOME MEASURES Disease-specific survival (DSS) and recurrence-free survival (RFS). RESULTS Of 344 patients older than 45 years with low-risk tumors, 148 (43%) received RAI and 196 (57%) were selected not to receive RAI. The patients who were treated without RAI were more likely to be female and have pT1N0 disease. The 5-year DSS and RFS were 100% and 98%, respectively. The presence of nodal metastases predicted poorer 5-year RFS within this group (99% vs 91%; P = .004). Of 188 patients younger than 45 years with high-risk tumors, 159 (85%) received RAI, and only 29 (15%) were selected not to receive RAI. The 5-year DSS and RFS for these patients were 100% and 95%, respectively. The presence of nodal metastases predicted poorer 5-year RFS within this group (100% vs 86%; P = .02). CONCLUSION Our study shows that the subgroup of patients who are older than 45 years with tumors that are smaller than 4 cm in greatest dimension and confined to the thyroid gland and who do not have nodal metastases can safely be treated without RAI.

[1]  M. Ringel,et al.  The Role of Radioactive Iodine in Salivary Gland Dysfunction , 2000, Ear, nose, & throat journal.

[2]  J. Tward,et al.  The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.

[3]  F. Jegoux,et al.  Pattern of lateral neck metastases in N0 papillary thyroid carcinoma , 2011, BMC Cancer.

[4]  P. Hall,et al.  Second primary malignancies in thyroid cancer patients , 2003, British Journal of Cancer.

[5]  S. Mandel,et al.  Radioactive iodine and the salivary glands. , 2003, Thyroid : official journal of the American Thyroid Association.

[6]  D. Elkins,et al.  Quality of life with well-differentiated thyroid cancer: treatment toxicities and their reduction. , 2004, Thyroid : official journal of the American Thyroid Association.

[7]  C. Begg,et al.  Prognostic factors in differentiated carcinoma of the thyroid gland. , 1992, American journal of surgery.

[8]  A. Sanabria,et al.  Late side effects of radioactive iodine on salivary gland function in patients with thyroid cancer , 2011, Head & neck.

[9]  J. Griggs,et al.  Use of radioactive iodine for thyroid cancer. , 2011, JAMA.

[10]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[11]  I. Ganly,et al.  Rising incidence of second cancers in patients with low‐risk (T1N0) thyroid cancer who receive radioactive iodine therapy , 2011, Cancer.

[12]  B. Malpani,et al.  Quantification of salivary gland function in thyroid cancer patients treated with radioiodine. , 1996, International journal of radiation oncology, biology, physics.

[13]  J. Watkinson,et al.  The British Thyroid Association guidelines for the management of thyroid cancer in adults , 2004, Nuclear medicine communications.

[14]  S. Straus,et al.  Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. , 2009, Thyroid : official journal of the American Thyroid Association.

[15]  W. Wiersinga,et al.  European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. , 2006, European journal of endocrinology.

[16]  E. Choi,et al.  Predictive Factors For Ipsilateral or Contralateral Central Lymph Node Metastasis in Unilateral Papillary Thyroid Carcinoma , 2009, Annals of surgery.

[17]  C. Silver,et al.  Paratracheal node dissection for well-differentiated cancer of the thyroid: indications, technique and results. , 2008, Auris, nasus, larynx.

[18]  J. Shah,et al.  Impact of lymph node metastasis in differentiated carcinoma of the thyroid: A matched‐pair analysis , 1996, Head & neck.

[19]  S. Larson,et al.  Salivary Gland Side Effects Commonly Develop Several Weeks After Initial Radioactive Iodine Ablation , 2009, Journal of Nuclear Medicine.

[20]  L. Kowalski,et al.  Clinical predictors of quality of life in patients with initial differentiated thyroid cancers. , 2009, Archives of otolaryngology--head & neck surgery.

[21]  C. Kirsch,et al.  Intermediate and long-term side effects of high-dose radioiodine therapy for thyroid carcinoma. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.